Tag: Diabetes
Zydus Lifesciences gets FDA final approvals for Silodosin and Pregabalin capsules
Zydus Lifesciences (formerly known as Cadila Healthcare) has secured final approvals from the US Food and Drug Administration (FDA) for Silodosin Capsules, 4 mg and ... Read More
Biocon partners with Zentiva for European marketing of Liraglutide
Biocon Limited has entered into a semi-exclusive partnership with Zentiva, a Czech pharma company for marketing its drug-device combination Liraglutide for the treatment and management ... Read More
Glenmark Pharmaceuticals launches Type 2 diabetes drug Zita D in India
Glenmark Pharmaceuticals has launched Zita D the brand name for Teneligliptin (20mg) + Dapagliflozin (5mg/10mg) fixed dose combination in India for the treatment of Type ... Read More
Zydus Lifesciences launches diabetes drugs Sitaglyn and Siglyn in India
Zydus Lifesciences (Cadila Healthcare) has rolled out the molecule Sitagliptin in India under the Sitaglyn and Siglyn brand names for the treatment of Type 2 ... Read More
FDA issues warning letter to Medtronic diabetes business
Medtronic said that it has been issued a warning letter from the US Food and Drug Administration (FDA) for its facility in Northridge, California, which ... Read More
Cipla signs licensing deal with Lilly to sell two diabetes drugs in India
Cipla has signed a licensing deal with the Indian subsidiary of US pharma giant Eli Lilly and Company (Lilly) pertaining to the latter’s diabetes treatments ... Read More
Lilly takes full ownership of biotech company Protomer Technologies
Eli Lilly and Company (Lilly) has taken full ownership of California-based biotech company Protomer Technologies in a deal that is potentially worth more than $1 ... Read More
AstraZeneca India scraps Dapagliflozin distribution deal with Abbott
AstraZeneca Pharma India (AstraZeneca India) said that it has scrapped its distribution agreement with Abbott Healthcare pertaining to its Type 2 diabetes drug Dapagliflozin in ... Read More
CenterLab’s anti-diabetic drug candidate CS02 meets primary endpoint in phase 2 trial
Taiwanese pharma company Center Laboratories (CenterLab) said that its anti-diabetic drug candidate CS02 has met the primary endpoint of a phase 2 clinical trial. According ... Read More
Medtronic secures $337m from Blackstone to develop diabetes technologies
Irish medical device company Medtronic has secured a $337 million product investment from Blackstone Life Sciences for advancing new, innovative products particularly designed to ease the ... Read More